ReviewAsian biomedicine : research, reviews and news2023
Lateral flow assay: a promising rapid point-of-care testing tool for infections and non-communicable diseases.
Review in Asian biomedicine : research, reviews and news, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- A Rational Optimization Approach for the Development of a Multiplexed Lateral Flow Immunoassay: Detection of Nonepithelial Ovarian Cancer Markers in Human Serum.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Evaluating a biochemical TB medication adherence test: Insights from image-based reporting through a patient companion app.PLOS global public health · 2026Article
- Urine-based PSMA detection for noninvasive prostate cancer diagnosis: recent advances, translational challenges, and future perspectives.Frontiers in oncology · 2026Review
- Next-Generation Diagnostic Technologies for Dengue Virus Detection: Microfluidics, Biosensing, CRISPR, and AI Approaches.Sensors (Basel, Switzerland) · 2025Review
- Highly Sensitive Detection of Anti-SARS-CoV-2 Antibodies in Human Serum Using Bloch Surface Wave Biosensor.Sensors (Basel, Switzerland) · 2025Article
- Recent advances in lateral flow devices and point-of-care diagnostics for highly pathogenic avian influenza A viruses.Journal of virology · 2025Review
- A novel and superior diagnostic test for feline leukemia virus: enhanced precision in rapid detecting viral antigen in blood, plasma and serum.Virology journal · 2025Article
- Diagnostic Innovations to Combat Antibiotic Resistance in Critical Care: Tools for Targeted Therapy and Stewardship.Diagnostics (Basel, Switzerland) · 2025Review
- Development of a point-of-care test for the simultaneous detection of respiratory syncytial virus and IL-33 as a disease biomarker in children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Advancing protein biosensors: redefining detection through innovations in materials, mechanisms, and applications for precision medicine and global diagnostics.RSC advances · 2025Review
- Article
- Biosensors and Bioassays for the Medical Detection ofCurrent medicinal chemistry · 2025Review
- Advancing clinical biochemistry: addressing gaps and driving future innovations.Frontiers in medicine · 2025Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The point-of-care testing (POCT) approach has established itself as having remarkable importance in diagnosing various infectious and non-communicable diseases (NCDs). The POCT approach has succeeded in meeting the current demand for having diagnostic strategies that can provide fast, sensitive, and highly accurate test results without involving complicated procedures. This has been accomplished by introducing rapid bioanalytical tools or biosensors such as lateral flow assays (LFAs). The production cost of these tools is very low, allowing developing countries with limited resources to utilize them or produce them on their own. Thus, their use has grown in various fields in recent years. More importantly, LFAs have created the possibility for a new era of incorporating nanotechnology in disease diagnosis and have already attained significant commercial success worldwide, making POCT an essential approach not just for now but also for the future. In this review, we have provided an overview of POCT and its evolution into the most promising rapid diagnostic approach. We also elaborate on LFAs with a special focus on nucleic acid LFAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.